PFIZER INC.

CatalYm appointed four experienced executives to accelerate visugromab's progression into late-stage clinical development following promising Phase 2a results.

Pfizer's PF-07248144, a first-in-class KAT6 inhibitor discovered by Australian researchers, has commenced Phase 3 clinical trials for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

The FDA plans to present data at next week's CDC Advisory Committee on Immunization Practices meeting claiming to link COVID-19 vaccines to 25 deaths in children, based on analysis of VAERS database reports.

Enveda Biosciences secured $150 million in Series D funding led by Premji Invest to advance its AI-powered drug discovery platform that mines natural molecules for therapeutic development.

Radiance Biopharma has signed an exclusive licensing agreement with Novatim for RB-601™, a first-in-class bispecific nanobody ADC targeting c-MET and EGFR receptors.

Biohaven's Vyglxia could become the first approved treatment for spinocerebellar ataxia, a rare genetic brain disorder affecting movement and coordination, with FDA decision expected between October and December.

Olema Oncology and Pfizer have announced a new clinical trial collaboration to evaluate the combination of palazestrant and atirmociclib in approximately 35 patients with ER+/HER2- metastatic breast cancer.

The FDA approved Pfizer-BioNTech's LP.8.1-adapted monovalent COVID-19 vaccine on August 27 for adults 65 and older and individuals aged 5-64 with high-risk conditions.

ACROBiosystems and DAAN Biotherapeutics signed a strategic MOU to establish a multi-faceted collaboration framework for developing precision immunotherapies targeting drug-resistant cancers.

Eli Lilly's Verzenio plus endocrine therapy demonstrated statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone in patients with HR+, HER2-, node-positive, high-risk early breast cancer.